International Journal of Medical Investigation
Wed, Jan 15, 2025
Volume 13, Issue 2 (6-2024)
Int J Med Invest 2024, 13(2): 84-91 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Moghadam M N, Shahri E S. Examination Of C-Peptide Levels In Plasma At The Beginning Of Type 1 Diabetes Diagnosis In Children During The Honeymoon Period. Int J Med Invest 2024; 13 (2) :84-91
URL: http://intjmi.com/article-1-1147-en.html
URL: http://intjmi.com/article-1-1147-en.html
Pediatric endocrinologist, Children and adolescents health research Center, Zahedan Medical University of Medical Sciences Zahedan, Iran
Abstract: (667 Views)
Background: C-peptide determination in the honeymoon phase is a practical approach to start or stop insulin-based treatment in patients suffering from type 1 diabetes (T1DM). The present study aimed to assess the C-peptide levels in plasma at the beginning of type 1 diabetes diagnosis in children during the honeymoon period.
Methods: Younger than 18 years old children with proven insulin-dependent diabetes who didn’t receive any insulin treatment were included in the study. Those related to non-T1DM (T2DM, MODY, and secondary diabetes) and primary insulin administration, were excluded. Totally, 30 patients were entered. Blood samples were collected and C-peptide levels, fasting and random glucose, blood glycosylated hemoglobin (HbA1C), and serum levels of GAD (anti-glutamic acid decarboxylase antibodies), IA-2 (anti-tyrosine phosphatase antibodies), ICA (islet cell antibodies), and IAA (insulin autoantibodies) were analyzed.
Results: The age of patients had a range of 1 to 17 years old. The honeymoon period had a range between 3 to 18 months. Only 7 out of 30 (23.33%) studied patients had C-peptide levels of <5 before the honeymoon period. Reversely, 23 out of 30 (76.66%) patients had C-peptide levels of <5 after the honeymoon period. Additionally, IAA, ICA, GAD, and TA2 autoantibodies were detected in 23.33% (7 out of 30 patients), 20% (6 out of 30 patients), 66.66% (20 out of 30 patients), and 23.33% (7 out of 30 patients), respectively.
Conclusion: These findings may show the high impact and role of GAD autoantibody and also C-peptide during the honeymoon period.
Methods: Younger than 18 years old children with proven insulin-dependent diabetes who didn’t receive any insulin treatment were included in the study. Those related to non-T1DM (T2DM, MODY, and secondary diabetes) and primary insulin administration, were excluded. Totally, 30 patients were entered. Blood samples were collected and C-peptide levels, fasting and random glucose, blood glycosylated hemoglobin (HbA1C), and serum levels of GAD (anti-glutamic acid decarboxylase antibodies), IA-2 (anti-tyrosine phosphatase antibodies), ICA (islet cell antibodies), and IAA (insulin autoantibodies) were analyzed.
Results: The age of patients had a range of 1 to 17 years old. The honeymoon period had a range between 3 to 18 months. Only 7 out of 30 (23.33%) studied patients had C-peptide levels of <5 before the honeymoon period. Reversely, 23 out of 30 (76.66%) patients had C-peptide levels of <5 after the honeymoon period. Additionally, IAA, ICA, GAD, and TA2 autoantibodies were detected in 23.33% (7 out of 30 patients), 20% (6 out of 30 patients), 66.66% (20 out of 30 patients), and 23.33% (7 out of 30 patients), respectively.
Conclusion: These findings may show the high impact and role of GAD autoantibody and also C-peptide during the honeymoon period.
References
1. 1- "Summary of Revisions: Standards of Care in Diabetes—2024." Diabetes Care 47, no. Supplement_1 (2024): S5-S10.
2- Akturk HK, McKee AM. Emerging Technologies and Therapeutics for Type 1 Diabetes. Endocrinology and Metabolism Clinics. 2024;53(1):81-91.
3- Wu S, Gao Y, Guo S, Fu L, Ying Y, Wu W, Hou L, Liang Y, Luo X. Characterization of newly diagnosed type 1 diabetes in children and adolescents from 2017 to 2022 in China: a single-center analysis. BMC pediatrics. 2024;24(1):13.
4- Minasian V, Nazari M. The association between type 1 diabetes and exercise/physical activity and prolongation of the honeymoon phase in patients. Life Sciences. 2023:122114.
5- Mittal M, Porchezhian P, Kapoor N. Honeymoon phase in type 1 diabetes mellitus: A window of opportunity for diabetes reversal?. World Journal of Clinical Cases. 2024;12(1):9.
6- Viswanathan A, Wood JR, Hatipoglu BA. What Is a Honeymoon in Type 1, Can It Go into Remission?. Endocrinology and Metabolism Clinics. 2023;52(1):175-85.
7- Fonolleda M, Murillo M, Vázquez F, Bel J, Vives-Pi M. Remission phase in paediatric type 1 diabetes: new understanding and emerging biomarkers. Hormone research in paediatrics. 2017;88(5):307-15.
8- Nwosu BU, Zhang B, Ayyoub SS, Choi S, Villalobos-Ortiz TR, Alonso LC, Barton BA. Children with type 1 diabetes who experienced a honeymoon phase had significantly lower LDL cholesterol 5 years after diagnosis. PLoS One. 2018;13(5):e0196912.
9- Washburn RL, Mueller K, Kaur G, Moreno T, Moustaid-Moussa N, Ramalingam L, Dufour JM. C-peptide as a therapy for type 1 diabetes mellitus. Biomedicines. 2021;9(3):270.
10- Shi X, Su W, Wang J, Huang P, Huang C, Zeng W, Liu W, Zhang Y, Lin M, Li X. Serum Low C-Peptide Levels Correlate With Low Muscle Mass in Patients With Type 2 Diabetes Mellitus. Diabetes Care. 2024;47(2):e14-6.
11- Iqbal S, Jayyab AA, Alrashdi AM, Reverté-Villarroya S. The predictive ability of c-peptide in distinguishing type 1 diabetes from type 2 diabetes: A systematic review and meta-analysis. Endocrine Practice. 2023;29(5):379-87.
12- Jamiołkowska-Sztabkowska M, Głowińska-Olszewska B, Bossowski A. C-peptide and residual β-cell function in pediatric diabetes–state of the art. Pediatric Endocrinology Diabetes and Metabolism. 2021;27(2):123-33.
13- Adolfsson P, Taplin CE, Zaharieva DP, Pemberton J, Davis EA, Riddell MC, McGavock J, Moser O, Szadkowska A, Lopez P, Santiprabhob J. ISPAD Clinical Practice Consensus Guidelines 2022: Exercise in children and adolescents with diabetes. Pediatric Diabetes. 2022;23(8):1341-72.
14- DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. The Lancet. 2018;391(10138):2449-62.
15- Katsarou A, Gudbjörnsdottir S, Rawshani A, Dabelea D, Bonifacio E, Anderson BJ, Jacobsen LM, Schatz DA, Lernmark Å. Type 1 diabetes mellitus. Nature reviews Disease primers. 2017;3(1):1-7.
16- Bowden SA. Partial remission (honeymoon phase) in type 1 diabetes mellitus. Frontiers Clin Drug Res Diabetes Obes.. 2017;4:1-20.
17- Sokołowska M, Chobot A, Jarosz-Chobot P. The honeymoon phase–what we know today about the factors that can modulate the remission period in type 1 diabetes. Pediatric Endocrinology Diabetes and Metabolism. 2016;22(2).
18- Mahzari M. Prolonged type 1 diabetes honeymoon period: Case report and review of the literature. King Khalid University Journal of Health Sciences. 2020 Jul 1;5(2):90-.
19- Nwosu BU. Partial Clinical Remission of Type 1 Diabetes Mellitus in Children: Clinical Applications and Challenges with its Definitions. European medical journal. Diabetes. 2019;4(1):89.
20- Rydzewska M, Kulesza M, Olszewska M, Jamiołkowska M, Łuczyński W, Głowińska-Olszewska B, Bossowski A. Clinical determinants of the remission phase in children with new-onset type 1 diabetes mellitus in two years of observation. Pediatric Endocrinology Diabetes and Metabolism. 2019;25(1):6-16.
21- Hwang JW, Kim MS, Lee DY. Factors Associated with C-peptide Levels after Diagnosis in Children with Type 1 Diabetes Mellitus. Chonnam medical journal. 2017;53(3):216-22.
22- Jones AG, Besser RE, Shields BM, McDonald TJ, Hope SV, Knight BA et al. Assessment of endogenous insulin secretion in insulintreated diabetes predicts postprandial glucose and treatment response to prandial insulin. BMC Endocr Disord 2012; 12: 6.
23- Jones AG, Hattersley AT. The clinical utility of C‐peptide measurement in the care of patients with diabetes. Diabetic medicine. 2013;30(7):803-17.
24- Faustman DL, Davis M. The Pancreas Secreting Insulin for Decades after Onset of Type I Diabetes—Implications for Care and Management. Major Topics in Type 1 Diabetes. 2015:21.
25- Ozen G, Zanfardino A, Confetto S, Piscopo A, Casaburo F, Tinto N, Iafusco F, Ozen G, Miraglia del Giudice E, Tasar MA, Yilmaz A. The Association of Autoimmune Diseases with Type 1 Diabetes Mellitus in Children Depends Also by the Length of Partial Clinical Remission Phase (Honeymoon). International Journal of Endocrinology. 2020;2020.
26- AL-Auqbi TF, Bahrani MA, AL-Khalidy NT. Dose the C-Peptide Level Predict Remission Phase in Type 1 Diabetes Mellitus Pediatric Patients. Iraqi Journal of Community Medicine. 2012;25(4):324-9.
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
